Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions
Results from clinical trials of a selective ionotropic glutamate receptor 5 (iGluR5) antagonist, LY5454694 tosylate, in 2 chronic pain conditions
复制标题
DOI：
10.1016/j.pain.2014.02.023
复制
发表时间：
2014-06-01
期刊：
影响因子：
7.4
通讯作者：
Prucka, William R.
中科院分区：
文献类型：
--
作者：
Chappell, Amy S.;Iyengar, Smriti;Prucka, William R.
本文报告了2项研究的结果，研究了LY545694治疗膝关节骨关节炎（OA）和糖尿病周围神经性疼痛（DPNP）引起的疼痛。研究I将患者随机分配至2种剂量的LY545694或安慰剂组，研究II将患者随机分配至3种剂量的LY545694、普瑞巴林或安慰剂组。在两项研究中，在主要（平均疼痛严重程度）或次要疗效指标方面均未观察到LY545694组和安慰剂组之间的显著差异。值得注意的是，研究I缺乏活性对照，并且在研究II中，普瑞巴林没有与安慰剂分开。在两项试验中，LY545694组治疗后出现的恶心、呕吐和头晕明显更常见（P
This article reports results of 2 studies investigating LY545694 in pain due to osteoarthritis (OA) of the knee and diabetic peripheral neuropathic pain (DPNP). Study I randomized patients to either of 2 doses of LY545694 or to placebo, and study II randomized patients to either of 3 doses of LY545694, to pregabalin, or to placebo. No significant differences between LY545694 groups and placebo were observed on the primary (average pain severity) or secondary efficacy measures in either study. Notably, study I lacked an active control, and, in study II, pregabalin, did not separate from placebo. Treatment-emergent nausea, vomiting, and dizziness were significantly more frequent in the LY545694 groups in both trials (P